Literature DB >> 28966903

Challenges and Opportunities with Predicting in Vivo Phase II Metabolism via Glucuronidation from in Vitro Data.

Shufan Ge1, Yifan Tu1, Ming Hu1.   

Abstract

Glucuronidation is the most important phase II metabolic pathway which is responsible for the clearance of many endogenous and exogenous compounds. To better understand the elimination process for compounds undergoing glucuronidation and identify compounds with desirable in vivo pharmacokinetic properties, many efforts have been made to predict in vivo glucuronidation using in vitro data. In this article, we reviewed typical approaches used in previous predictions. The problems and challenges in prediction of glucuronidation were discussed. Besides that different incubation conditions can affect the prediction accuracy, other factors including efflux / uptake transporters, enterohepatic recycling, and deglucuronidation reactions also contribute to the disposition of glucuronides and make the prediction more difficult. PBPK modeling, which can describe more complicated process in vivo, is a promising prediction strategy which may greatly improve the prediction of glucuronidation and potential DDIs involving glucuronidation. Based on previous studies, we proposed a transport-glucuronidation classification system, which was built based on the kinetics of both glucuronidation and transport of the glucuronide. This system could be a very useful tool to achieve better in vivo predictions.

Entities:  

Keywords:  Glucuronidation; PBPK; Prediction; Transport-Glucuronidation Classification System; Transporter

Year:  2016        PMID: 28966903      PMCID: PMC5613675          DOI: 10.1007/s40495-016-0076-8

Source DB:  PubMed          Journal:  Curr Pharmacol Rep        ISSN: 2198-641X


  114 in total

1.  In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance.

Authors:  M G Soars; B Burchell; R J Riley
Journal:  J Pharmacol Exp Ther       Date:  2002-04       Impact factor: 4.030

2.  Determination of blood and other tissue concentrations of paracetamol in dog and man.

Authors:  J R GWILT; A ROBERTSON; E W McCHESNEY
Journal:  J Pharm Pharmacol       Date:  1963-07       Impact factor: 3.765

3.  Expression of the conjugate export pump encoded by the mrp2 gene in the apical membrane of kidney proximal tubules.

Authors:  T P Schaub; J Kartenbeck; J König; O Vogel; R Witzgall; W Kriz; D Keppler
Journal:  J Am Soc Nephrol       Date:  1997-08       Impact factor: 10.121

4.  Interaction of digitalis-like compounds with liver uptake transporters NTCP, OATP1B1, and OATP1B3.

Authors:  Elnaz Gozalpour; Rick Greupink; Heleen M Wortelboer; Albert Bilos; Marieke Schreurs; Frans G M Russel; Jan B Koenderink
Journal:  Mol Pharm       Date:  2014-05-06       Impact factor: 4.939

5.  Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats.

Authors:  Masato Horikawa; Yukio Kato; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

6.  Transport of the coumarin metabolite 7-hydroxycoumarin glucuronide is mediated via multidrug resistance-associated proteins 3 and 4.

Authors:  Hanneke G M Wittgen; Jeroen J M W van den Heuvel; Petra H H van den Broek; Sanna Siissalo; Geny M M Groothuis; Inge A M de Graaf; Jan B Koenderink; Frans G M Russel
Journal:  Drug Metab Dispos       Date:  2012-03-12       Impact factor: 3.922

7.  SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients.

Authors:  Hugues Michelon; Jörg König; Antoine Durrbach; Lina Quteineh; Céline Verstuyft; Valérie Furlan; Sophie Ferlicot; Alexia Letierce; Bernard Charpentier; Martin F Fromm; Laurent Becquemont
Journal:  Pharmacogenomics       Date:  2010-12       Impact factor: 2.533

8.  Characterization of chrysin glucuronidation in UGT1A1-overexpressing HeLa cells: elucidating the transporters responsible for efflux of glucuronide.

Authors:  Enxi Quan; Huailing Wang; Dong Dong; Xingwang Zhang; Baojian Wu
Journal:  Drug Metab Dispos       Date:  2015-01-16       Impact factor: 3.922

9.  In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine.

Authors:  Sam Boase; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

10.  Molecular cloning and functional characterization of the bovine (Bos taurus) organic anion transporting polypeptide Oatp1a2 (Slco1a2).

Authors:  Joachim Geyer; Barbara Döring; Klaus Failing; Ernst Petzinger
Journal:  Comp Biochem Physiol B Biochem Mol Biol       Date:  2004-03       Impact factor: 2.231

View more
  4 in total

1.  Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial.

Authors:  Neal Shore; Christian Zurth; Robert Fricke; Hille Gieschen; Kristina Graudenz; Mikko Koskinen; Bart Ploeger; Jonathan Moss; Olaf Prien; Gustavo Borghesi; Oana Petrenciuc; Teuvo L Tammela; Iris Kuss; Frank Verholen; Matthew R Smith; Karim Fizazi
Journal:  Target Oncol       Date:  2019-10       Impact factor: 4.493

Review 2.  Irinotecan-Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview.

Authors:  Mateusz Kciuk; Beata Marciniak; Renata Kontek
Journal:  Int J Mol Sci       Date:  2020-07-12       Impact factor: 5.923

3.  Synthesis and Preclinical Evaluation of the First Carbon-11 Labeled PET Tracers Targeting Substance P1-7.

Authors:  Aleksandra Pekošak; Janez Ž Bulc; Špela Korat; Robert C Schuit; Esther Kooijman; Ricardo Vos; Marissa Rongen; Mariska Verlaan; Kevin Takkenkamp; Wissam Beaino; Alex J Poot; Albert D Windhorst
Journal:  Mol Pharm       Date:  2018-10-25       Impact factor: 4.939

4.  Novel testing strategy for prediction of rat biliary excretion of intravenously administered estradiol-17β glucuronide.

Authors:  Annelies Noorlander; Eric Fabian; Bennard van Ravenzwaay; Ivonne M C M Rietjens
Journal:  Arch Toxicol       Date:  2020-11-07       Impact factor: 5.153

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.